Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors
22 Junio 2023 - 12:00AM
Saint-Herblain
(France), June
22,
2023 – Valneva SE (Nasdaq: VALN;
Euronext Paris: VLA), a specialty vaccine company, today announced
that its Supervisory Board has recommended a change of governance
model.
The Company’s Supervisory Board members voted in
favor of recommending to the shareholders to transition from the
Company’s current two-tier governance model, which includes a
Supervisory Board and a Management Board, to a one-tier model led
by a Board of Directors, with CEO Thomas Lingelbach included as
an executive member. The Supervisory Board’s proposal also
recommends the establishment of an Executive Committee to be
comprised of, among others, the members of the current Management
Board.
This proposed change in Valneva’s governance
structure will be submitted to the vote of the Company’s
shareholders at an Extraordinary General Meeting later this
year.
Thomas Lingelbach,
Chief
Executive
Officer of
Valneva, commented: “As we continue to grow, we believe
that the proposed change of the Company´s governance will further
improve effectiveness and efficiency in the Company´s leadership by
applying a governance model that is more common in our
industry.”
About Valneva SEWe are a
specialty vaccine company focused on the development, manufacturing
and commercialization of prophylactic vaccines for infectious
diseases. We take a highly specialized and targeted approach to
vaccine development by focusing on vaccine solutions addressing
unmet medical needs to ensure we can make a difference to peoples’
lives. We apply our deep understanding of vaccine science,
including our expertise across multiple vaccine modalities, and our
established vaccine development capabilities, to develop vaccines
against diseases which are not yet vaccine-preventable, or for
which there are limited effective treatment options. Today, we are
leveraging our expertise and capabilities to rapidly advance a
broad range of vaccines into and through the clinic, including
candidates against the chikungunya virus and Lyme disease.
Valneva
Investor and Media ContactsLaetitia Bachelot-FontaineVP
Global Communications & European Investor RelationsM +33 (0)6
4516
7099laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing, results and
completion of research, development and clinical trials for product
candidates, to regulatory approval of product candidates and review
of existing products. In addition, even if the actual results or
development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or
developments of Valneva may not be sustained in the future. In some
cases, you can identify forward-looking statements by words such as
“could,” “should,” “may,” “expects,” “anticipates,” “believes,”
“intends,” “estimates,” “aims,” “targets,” or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
and delays involved in the development and manufacture of vaccines,
unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact
of the global and European credit crisis, and the ability to obtain
or maintain patent or other proprietary intellectual property
protection. Success in preclinical studies or earlier clinical
trials may not be indicative of results in future clinical trials.
In light of these risks and uncertainties, there can be no
assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2023_06_22_VLA_Governance_Model_Change_PR_EN_Final
Valneva (EU:VLA)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Valneva (EU:VLA)
Gráfica de Acción Histórica
De May 2023 a May 2024